Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Bone. 2020 Apr 28;137:115391. doi: 10.1016/j.bone.2020.115391

Figure 1. Genetic or pharmacological inhibition of CypD inhibits MPTP opening in BMSCs.

Figure 1.

A) BMSCs were isolated from mouse long bones, cultured and subjected to various assays; B) BMSCs from CypD+/+ and CypD−/− littermates were subjected to calcium retention capacity (CRC) assay which measures sensitivity to MPTP opening after excessive calcium uptake by mitochondria. CypD−/− BMSC mitochondria accumulate more calcium before opening the pore and, thus show higher CRC; C) CRC was calculated and plotted as a fold change of control CypD+/+. CypD−/− BMSCs show significantly higher CRC and, thus lower MPTP opening when compared to CypD+/+ controls; D) C57BL/6J BMSCs treated with the CypD inhibitor, NIM811, show significantly higher CRC and, thus lower MPTP opening when compared to vehicle-treated controls. Data in (B) are Means ± SD (n = 4). Plots in (C) and (D) show actual data points and calculated means. *, p < 0.05, determined by unpaired t-test. See also Supplementary Figure S1.